Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Legal adult age and able to give Informed Consent.~* Adult subjects with a diagnosis of ADPKD. A diagnosis of ADPKD (age 18 or 20-50) required several cysts in each kidney (3 if by sonography, 5 if by CT or MRI) in those with a family history of ADPKD and 10 cysts (by any radiologic method) in each kidney and exclusion of other cystic kidney diseases if there was no family history.~* Willingness to comply with reproductive precautions, if female.~* Estimated creatinine clearance ≥ 60 mL/min. Estimated from serum creatinine during screening using Cockcroft-Gault with correction for gender and race, where possible.~* Rapidly progressive kidney growth (total volume ≥ 750 cc) by magnetic resonance imaging (MRI) at randomization.~Exclusion Criteria:~* Prior exposure to tolvaptan or other experimental PKD therapies.~* Currently taking medication for purpose of affecting PKD cysts.~* Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods.~* In the opinion of the study investigator or sponsor may present a safety risk or confound study objectives.~* Patients who are unlikely to adequately comply with study procedures.~* Patients having contraindications to MRI.~* Patients taking medications or having any illnesses likely to affect ADPKD outcomes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo (upon awakening and 9 hours later) orally for 36 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).